Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 84, Issue 2, 2013, Pages 130-135

  Pondal, Margarita ^a   Marras, Connie ^a   Miyasaki, Janis ^a   Moro, Elena ^a   Armstrong, Melissa J ^a   Strafella, Antonio P ^a   Shah, Binit B ^a   Fox, Susan ^a   Prashanth, L K ^a   Phielipp, Nicolas ^a   Lang, Anthony E ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; PERGOLIDE; PRAMIPEXOLE; ROPINIROLE;

ADDICTION; ADULT; AGED; ANXIETY; ARTICLE; AUTONOMIC DYSFUNCTION; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DEPRESSION; DIAPHORESIS; DIZZINESS; DOPAMINE AGONIST WITHDRAWAL SYNDROME; DRUG DOSE INCREASE; DRUG WITHDRAWAL; FATIGUE; FEMALE; FLUSHING; FUNCTIONAL DISEASE; HALLUCINATION; HUMAN; HYPERSOMNIA; HYPOTENSION; IMPULSE CONTROL DISORDER; INSOMNIA; IRRITABILITY; MALE; MEDICAL RECORD REVIEW; NAUSEA; PAIN; PANIC; PARKINSON DISEASE; PERIPHERAL EDEMA; PRIORITY JOURNAL; SIDE EFFECT; SUICIDAL IDEATION; WITHDRAWAL SYNDROME;

EID: 84872686587     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2012-302684     Document Type: Article

References (29)

1. Evans AH, Strafella AP, Weintraub D, et al. Impulsive and compulsive behaviors in Parkinson's disease. Mov Disord 2009;24:1561e70.
2. Evans AH, Lawrence AD, Cresswell SA, et al. Compulsive use of dopaminergic drug therapy in Parkinson's disease: reward and anti-reward. Mov Disord 2010;25:867e76.
3. Giovannoni G, O'sullivan JD, Turner K, et al. Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry 2000;68:423e8.
4. Lim SY, Evans AH, Miyasaki JM. Impulse control and related disorders in Parkinson's disease: review. Ann NY Acad Sci 2008;1142:85e107.
5. Pezzella FR, Colosimo C, Vanacore N, et al. Prevalence and clinical features of hedonistic homeostatic dysregulation in Parkinson's disease. Mov Disord 2005;20:77e81.
6. Weintraub D, Koester J, Potenza MN, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol 2010;67:589e95.
7. Rabinak CA, Nirenberg MJ. Dopamine agonist withdrawal syndrome in Parkinson disease. Arch Neurol 2010;67:58e63.
8. Evans AH, Lees AJ. Dopamine dysregulation syndrome in Parkinson's disease. Curr Opin Neurol 2004;17:393e8.
9. Lawrence AD, Evans AH, Lees AJ. Compulsive use of dopamine replacement therapy in Parkinson's disease: reward systems gone awry? Lancet Neurol 2003;2:595e604.
10. O'Sullivan SS, Evans AH, Lees AJ. Dopamine dysregulation syndrome: an overview of its epidemiology, mechanisms and management. CNS Drugs 2009;23:157e70.
11. Nirenberg MJ. Dopamine agonist withdrawal syndrome and non-motor symptoms after Parkinson's disease surgery. Brain 2010;133:e155.
12. Gallagher DA, O'Sullivan SS, Evans AH, et al. Pathological gambling in Parkinson's disease: risk factors and differences from dopamine dysregulation. An analysis of published case series. Mov Disord 2007;22:1757e63.
13. Voon V, Hassan K, Zurowski M, et al. Prevalence of repetitive and reward-seeking behaviors in Parkinson disease. Neurology 2006;67:1254e7.
14. Voon V, Fernagut PO, Wickens J, et al. Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disorders. Lancet Neurol 2009;8:1140e9.
15. Okai D, Samuel M, Askey-Jones S, et al. Impulse control disorders and dopamine dysregulation in Parkinson's disease: a broader conceptual framework. Eur J Neurol 2011;18:1379e83.
16. Thobois S, Ardouin C, Lhommee E, et al. Non-motor dopamine withdrawal syndrome after surgery for Parkinson's disease: predictors and underlying mesolimbic denervation. Brain 2010;133:1111e27.
17. Hughes AJ, Daniel SE, Kilford L, et al. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181e4.
18. Evans AH, Katzenschlager R, Paviour D, et al. Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome. Mov Disord 2004;19:397e405.
19. Limotai N, Oyama G, Go C, et al. Addiction-like manifestations and Parkinson's disease: a large single center 9-year experience. Int J Neurosci 2012;122:145e53.
20. Cunnington AL, White L, Hood K. Identification of possible risk factors for the development of dopamine agonist withdrawal syndrome in Parkinson's disease. Parkinsonism Relat Disord. Published Online First: 6 June 2012.
21. van Rooden SM, Heiser WJ, Kok JN, et al. The identification of Parkinson's disease subtypes using cluster analysis: a systematic review. Mov Disord 2010;25:969e78.
22. Weiss HD, Hirsch ES, Williams JR, et al. Detection of impulse control disorders in Parkinson disease patients. Neurologist 2010;16:406e7.
23. Tippmann-Peikert M, Park JG, Boeve BF, et al. Pathologic gambling in patients with restless legs syndrome treated with dopaminergic agonists. Neurology 2007;68:301e3.
24. d'Orsi G, Demaio V, Specchio LM. Pathological gambling plus hypersexuality in restless legs syndrome: a new case. Neurol Sci 2011;32:707e9.
25. Dang D, Cunnington D, Swieca J. The emergence of devastating impulse control disorders during dopamine agonist therapy of the restless legs syndrome. Clin Neuropharmacol 2011;34:66e70.
26. Dodd ML, Klos KJ, Bower JH, et al. Pathological gambling caused by drugs used to treat Parkinson disease. Arch Neurol 2005;62:1377e81.
27. Szarfman A, Doraiswamy PM, Tonning JM, et al. Association between pathologic gambling and parkinsonian therapy as detected in the Food and Drug Administration adverse event database. Arch Neurol 2006;63:299e300.
28. Voon V, Hassan K, Zurowski M, et al. Prospective prevalence of pathologic gambling and medication association in Parkinson disease. Neurology 2006;66:1750e2.
29. Montastruc JL, Schmitt L, Bagheri H. Pathological gambling behavior in a patient with Parkinson's disease treated with levodopa and bromocriptine. Rev Neurol (Paris) 2003;159:441e3.